MA30144B1 - Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison - Google Patents

Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison

Info

Publication number
MA30144B1
MA30144B1 MA31089A MA31089A MA30144B1 MA 30144 B1 MA30144 B1 MA 30144B1 MA 31089 A MA31089 A MA 31089A MA 31089 A MA31089 A MA 31089A MA 30144 B1 MA30144 B1 MA 30144B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
binding partners
protein interaction
bcl protein
Prior art date
Application number
MA31089A
Other languages
English (en)
Inventor
Alfredo C Castro
Michael J Grogan
Edward B Holson
Brian T Hopkins
Nii O Koney
Stephane Peluso
Daniel A Snyder
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of MA30144B1 publication Critical patent/MA30144B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention se rapporte à des composés hétérocycliques qui lient les protéines Bcl et qui inhibent la fonction de Bcl, à des compositions contenant de tels composés, et à des procédés de traitement et de modulation de troubles associés à l'hyperprolifération, comme le cancer.
MA31089A 2005-12-16 2008-07-04 Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison MA30144B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75098705P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
MA30144B1 true MA30144B1 (fr) 2009-01-02

Family

ID=38024107

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31089A MA30144B1 (fr) 2005-12-16 2008-07-04 Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison

Country Status (26)

Country Link
US (2) US7745464B2 (fr)
EP (1) EP1973875B1 (fr)
JP (1) JP5341521B2 (fr)
KR (1) KR101373911B1 (fr)
CN (1) CN101374807B (fr)
AR (1) AR058855A1 (fr)
AU (1) AU2006329879B2 (fr)
BR (1) BRPI0619968A2 (fr)
CA (1) CA2633958C (fr)
EC (1) ECSP088607A (fr)
ES (1) ES2494765T3 (fr)
IL (1) IL192023A (fr)
JO (1) JO2918B1 (fr)
MA (1) MA30144B1 (fr)
MX (1) MX2008007687A (fr)
MY (1) MY153232A (fr)
NO (1) NO20083050L (fr)
NZ (1) NZ569660A (fr)
PE (1) PE20071033A1 (fr)
RU (1) RU2424230C2 (fr)
SA (1) SA06270462B1 (fr)
SG (1) SG170727A1 (fr)
TN (1) TNSN08258A1 (fr)
TW (1) TWI403320B (fr)
WO (1) WO2007075387A1 (fr)
ZA (1) ZA200805822B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842815B2 (en) * 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
CN101906056B (zh) * 2009-06-04 2013-10-30 中国科学院广州生物医药与健康研究院 作为m2抑制剂的环烷胺类化合物及其应用
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
FR3048698B1 (fr) * 2016-03-11 2021-03-05 Univ Claude Bernard Lyon Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
TWI873185B (zh) 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1029227C (zh) * 1989-02-08 1995-07-05 大制药株式会社 苯衍生物的制备方法
CA2174838A1 (fr) 1993-11-24 1995-06-01 John Wityak Nouveaux antagonistes de recepteur de fibrinogene, a base d'isoxazoline et d'isoxazole
US6693123B2 (en) * 1995-11-06 2004-02-17 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
KR100399361B1 (ko) 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
EP1125925A1 (fr) * 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Dérivés amines pour le traitement de l'apoptose
US7018988B2 (en) * 2000-03-27 2006-03-28 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
US6703382B2 (en) 2000-08-16 2004-03-09 Georgetown University Medical Center Small molecule inhibitors targeted at Bcl-2
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US7855183B2 (en) 2000-11-10 2010-12-21 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US20040147473A1 (en) 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
ATE474568T1 (de) 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
AU2003223708A1 (en) * 2002-04-23 2003-11-10 Axys Pharmaceuticals, Inc. Novel phenyl derivatives as inducers of apoptosis
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
KR20050058507A (ko) * 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
AU2004247559B2 (en) * 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
WO2005026156A1 (fr) * 2003-09-16 2005-03-24 Astrazeneca Ab Derives de quinazoline
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
KR101195351B1 (ko) 2004-06-17 2012-10-29 인피니티 디스커버리, 인코포레이티드 Ｂｃｌ 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
JPWO2006025360A1 (ja) 2004-08-30 2008-05-08 三菱レイヨン株式会社 光学用共重合体及びそれからなる成形体
TW200626142A (en) * 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests

Also Published As

Publication number Publication date
IL192023A (en) 2014-06-30
JP5341521B2 (ja) 2013-11-13
US20070155705A1 (en) 2007-07-05
TW200811100A (en) 2008-03-01
US8304428B2 (en) 2012-11-06
HK1119704A1 (en) 2009-03-13
EP1973875A1 (fr) 2008-10-01
EP1973875B1 (fr) 2014-06-11
CA2633958C (fr) 2014-04-01
AR058855A1 (es) 2008-02-27
IL192023A0 (en) 2008-12-29
US7745464B2 (en) 2010-06-29
AU2006329879A1 (en) 2007-07-05
MY153232A (en) 2015-01-29
ZA200805822B (en) 2009-03-25
WO2007075387A1 (fr) 2007-07-05
JO2918B1 (en) 2015-09-15
JP2009519946A (ja) 2009-05-21
TWI403320B (zh) 2013-08-01
AU2006329879B2 (en) 2012-06-21
PE20071033A1 (es) 2007-11-26
MX2008007687A (es) 2008-09-26
US20100190791A1 (en) 2010-07-29
SA06270462B1 (ar) 2011-10-03
KR101373911B1 (ko) 2014-03-12
RU2424230C2 (ru) 2011-07-20
CA2633958A1 (fr) 2007-07-05
CN101374807A (zh) 2009-02-25
AU2006329879A8 (en) 2008-08-07
ES2494765T3 (es) 2014-09-16
KR20080077017A (ko) 2008-08-20
SG170727A1 (en) 2011-05-30
ECSP088607A (es) 2008-08-29
NZ569660A (en) 2010-07-30
RU2008128569A (ru) 2010-01-27
NO20083050L (no) 2008-09-10
BRPI0619968A2 (pt) 2011-10-25
CN101374807B (zh) 2013-10-09
TNSN08258A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30673B1 (fr) Composes et procedes d'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
MA31067B1 (fr) Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.
MA28702B1 (fr) Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
WO2003105840A3 (fr) Inhibiteurs de sphingosine kinase
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
MA31683B1 (fr) Composes et procedes pour moduler fxr
TNSN08258A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ID29552A (id) Senyawa-senyawa triazola dan penggunaannya
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
DK0912734T3 (da) Kimæriske heteromultimer-adhæsiner
MA28646B1 (fr) Entites, compositions chimiques et procedes
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
PT1214600E (pt) Determinacao de proteinas de ligacao a adrenomedulina
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
EP1613348A4 (fr) Procedes de modulation de l'angiogenese avec de compositions d'apeline
MA31526B1 (fr) Nouveaux herbicides
ATE443044T1 (de) Tace inhibitoren
MA31562B1 (fr) Macrocycles et leurs utilisations